

# UC Irvine

## UC Irvine Previously Published Works

### Title

On the early life origins of vulnerability to opioid addiction.

### Permalink

<https://escholarship.org/uc/item/7zq2d21b>

### Journal

Molecular psychiatry, 26(8)

### ISSN

1359-4184

### Authors

Levis, Sophia C  
Bentzley, Brandon S  
Molet, Jenny  
[et al.](#)

### Publication Date

2021-08-01

### DOI

10.1038/s41380-019-0628-5

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# On the early life origins of vulnerability to opioid addiction

Sophia C. Levis<sup>1,2</sup> • Brandon S. Bentzley<sup>3</sup> • Jenny Molet<sup>2</sup> • Jessica L. Bolton<sup>2</sup> • Christina R. Perrone<sup>1</sup> • Tallie Z. Baram<sup>2,4</sup> • Stephen V. Mahler<sup>1</sup>

## *Abstract*

The origins and neural bases of the current opioid addiction epidemic are unclear. Genetics plays a major role in addiction vulnerability, but cannot account for the recent exponential rise in opioid abuse, so environmental factors must contribute. Individuals with history of early life adversity (ELA) are disproportionately prone to opioid addiction, yet whether ELA interacts with factors such as increased access to opioids to directly influence brain development and function, and cause opioid addiction vulnerability, is unknown. We simulated ELA in female rats and this led to a striking opioid addiction-like phenotype. This was characterized by resistance to extinction, increased relapse-like behavior, and, as in addicted humans, major increases in opioid economic demand. By contrast, seeking of a less salient natural reward was unaffected by ELA, whereas demand for highly palatable treats was augmented. These discoveries provide novel insights into the origins and nature of reward circuit malfunction that may set the stage for addiction.

## **Introduction**

The devastating epidemic of opioid addiction in the United States is enormously costly, in both human life and economically [1]. Genetics plays a major role in addiction vulnerability, but cannot account for this recent rise in opioid abuse, so environmental factors (e.g., increased access to prescription opioids) must contribute [2–4]. Notably, substance use disorders are most prevalent among those who experienced early life poverty and trauma, and given their overrepresentation in this population, women are especially vulnerable [5–9]. However, it is yet unclear whether early life adversity actually causes vulnerability to opioid use disorder through alterations of the maturation and function of pleasure/reward circuits.

In humans, separating the influences of ELA from the roles of genetics and other contributing factors is complex [10]. Therefore, we simulated resource scarcity in rats during a short, defined postnatal sensitive period by limiting bedding and nesting materials in the cage (LBN) [11, 12]. This leads to aberrant maturation of brain circuits under-lying reward and stress [12], which are crucially implicated in addiction to a range of abused drugs.

Here, we tested whether ELA promotes use, seeking, and addiction to opioid drugs, and compared these behaviors with seeking of natural rewards including highly palatable food, all indicative of specific alterations in reward circuit function. We report here on a phenotype of opioid addiction-like behavior in ELA-experienced female rats. This was characterized by resistance to extinction, increased relapse-like behavior, and, as in addicted humans, major

increases in economic demand. By contrast, seeking of a less salient natural reward was unaffected by ELA, whereas demand for highly palatable food was also augmented.

## **Materials and methods**

### **Animals**

Primiparous, timed-pregnant Sprague-Dawley rats were obtained from Envigo (Livermore, CA) on E15, and maintained in an uncrowded, quiet animal facility room on a 12 h light/dark cycle. Parturition was checked daily, and the day of birth was considered postnatal day (PD) 0. On PD2, litters were mixed and both male and female pups were assigned to ELA and control (CTL) groups. Rats were weaned at PD21, and females were then housed in groups of 2–4, with a 12 h reverse light cycle. Food and water were available ad libitum throughout all experiments. All procedures were approved by the University of California Irvine Institutional Animal Care and Use Committee, and conducted in accordance with the National Institutes of Health guide for the care and use of laboratory animals.

### **The limited bedding and nesting (LBN) model of early life adversity**

On PD2, pups from at least two litters were gathered, and pups were assigned at random to each dam in equal numbers of male and female, to prevent potential confounding effect of genetic variables or litter size. Dams and pups assigned to the LBN group were transferred to cages fitted with a plastic-coated mesh platform sitting ~2.5 cm above the cage floor. Bedding sparsely covered the cage floor under the platform, and one-half of a 24.2 cm × 23.5 cm paper towel was provided for nesting material. Control group (CTL) dams and pups were placed in cages containing a standard amount of bedding (~0.33 cubic feet of shredded corn cob) without a platform, and one full paper towel. CTL and LBN cages remained undisturbed during PD2–9, during which maternal behaviors were monitored as previously described [13–15]. On PD10, animals were all transferred to CTL condition cages.

### **Intravenous catheter surgery**

At approximately PD70, rats were deeply anesthetized with isoflurane (2–2.5%) and chronic indwelling catheters were inserted into the right jugular vein, exiting 2 cm caudal to the scapulae. Meloxicam (1 mg/kg, i.p.) for postsurgical analgesia, and prophylactic antibiotic cefazolin (0.2 ml, i.v.; 10 mg/0.1 ml) were given perioperatively. After 5 days of recovery, catheters were flushed daily following each opioid self-administration session with cefazolin (10 mg/0.1 ml) and heparin lock solution (10 U/0.1 ml) to maintain catheter patency.

### **Drugs**

Heroin (diamorphine) HCl was provided by the National Institute on Drug Abuse (NIDA) Drug Supply Program (Research Triangle Park, NC, USA) and Cayman Chemical Company (Ann Arbor, MI, USA), and remifentanyl HCl was provided by the NIDA Drug Supply Program. All drugs were dissolved in sterile 0.9% saline for experimental use. Animals self-administered intravenous heroin at a concentration of 0.1 mg/kg/infusion during acquisition, and 0.05 mg/kg/infusion during maintenance of heroin self-administration. For the remifentanyl behavioral

economic task, remifentanyl was self-administered at decreasing concentrations over successive 10-min bins, as follows: 1.92, 1.08, 0.608, 0.342, 0.192, 0.108, 0.0609, 0.0341, 0.0193, 0.0108, 0.00611  $\mu\text{g}$  remifentanyl/infusion.

### **Behavioral/Functional tests**

M&M candies consumption, heroin self-administration, extinction, reinstatement, and remifentanyl demand tests were all performed in the same female rats ( $n = 16$ ). Sucrose preference tests were performed in a separate cohort of females ( $n = 24$ ). To further examine the effects of ELA on economic demand, female rats from a third cohort underwent, sequentially, both food (chow and palatable), and then remifentanyl demand tasks ( $n = 17$ ). Sample sizes were chosen based on observed effect sizes in our prior reports [11–14].

### **Sucrose preference**

Adult ELA and CTL females underwent a two-bottle home cage sucrose preference test [14]. The test consisted of two phases: 1 week of habituation to two bottles containing 50 ml tap water, followed by 2 weeks of sucrose consumption. In the second phase, one of the bottles was switched to contain 50 ml of 1.5% sucrose. The left/right position of the bottles was counterbalanced to obviate side bias. Fluid consumption was measured each morning, and drinking solution was refreshed to 50 ml daily.

### **M&M consumption**

Rats were given a 3-day test for free intake of M&M brand chocolate candies (Mars, McLean, VA) prior to catheterization and opiate self-administration training. On three consecutive days, animals were habituated to tub cages for 1 h, and then given ad libitum access to chocolate M&M's for 1 h. M&M consumption (g) was totaled over all 3 days for analysis.

### **Acquisition and maintenance of heroin self-administration**

Self-administration training and testing took place in Med Associates operant chambers within sound-attenuating boxes, each equipped with two retractable levers with white lights above them, a white house light, and a tone generator. Intravenous heroin was administered via a pump located outside the sound-attenuating box. Rats received daily 2-h self-administration sessions, when pressing on the “active” lever yielded a heroin infusion of 0.1 mg/kg (acquisition days 1–3) or 0.05 mg/kg (maintenance days 4–17), achieved by varying infusion volume based on animals' weight. Heroin infusions were accompanied by concurrent 2.9-kHz tone and lever light illumination for 3.6 s (Fixed Ratio 1 schedule: FR1). A 20-s timeout period (signaled by turning off the house light) followed each infusion/cue presentation, during which additional lever presses were recorded but had no consequence. Pressing on the second “inactive” lever was recorded but had no consequence. Doses were chosen that have previously been shown to sustain self-administration [16].

### **Heroin extinction and reinstatement**

Following heroin self-administration, rats received extinction training for a minimum of 7 days, or until an extinction criterion of two consecutive days of less than 20 active lever presses was

met. During extinction training, presses on both levers were recorded but had no consequences. Upon meeting the extinction criterion, rats underwent a cue-induced reinstatement test, during which one presentation of the previously drug-paired light and tone cue was delivered 10 s after the start of the session, then presses on the active lever yielded additional cue presentations as in self-administration training, but no heroin. Next, rats underwent a minimum of 2 additional extinction training days until extinction criterion was reattained, after which they underwent a heroin-primed reinstatement test. The rats received an experimenter-administered injection of heroin (0.25 mg/kg, s.c. [16]), or saline vehicle, immediately prior to being placed into the operant boxes for a 2-h session. Lever presses were recorded but did not yield additional heroin or cues (extinction conditions). All animals received both heroin and vehicle-primed reinstatement tests on separate days in counterbalanced order. Again, 2+ additional extinction training days occurred between primed reinstatement tests to reestablish extinction criterion. Following reinstatement tests, catheter patency was confirmed by administering intravenous brevipal (0.1–0.2 ml, 5 mg/ml). Rats with catheter failure were recatheterized in the left jugular vein, and allowed to recover prior to starting behavioral economic thresholding procedures.

### **Behavioral economic thresholding procedure**

Rats were trained on a previously described within-session economic thresholding procedure [17–20]. In order to avoid undesired effects of drug satiety on responding due to the long half-life of heroin, the short-acting opioid remifentanyl, a fentanyl analog, was used for this task. On each training day, presses on the active lever delivered remifentanyl and cue presentations on an FR1 schedule. The duration of each self-administered cue/infusion was decreased every 10 min across the 110-min session, requiring rats to exert increasing effort over time to maintain the desired blood level of drug [19, 20]. Drug intake was determined at the various response requirements (i.e., costs) and consumption data was then modeled with an exponential demand equation:  $\ln Q = \ln Q_0 + k(e^{-\alpha Q_0 C} - 1)$  as previously described [17–19], yielding variables corresponding to hedonic set-point ( $Q_0$ , reflecting extrapolated value of remifentanyl at price 0) and motivation ( $\alpha$ , reflecting demand elasticity). Rats were run daily on the threshold procedure for 14 days, and behavior derived from the average of the last 5 days was analyzed as described above.

### **Palatable and nutritive food thresholding procedure**

Rats were trained on a modified economic thresholding procedure [21] to assess demand for highly palatable food pellets containing sucrose (52%), fat (6.3%), and protein (20.2%), and normal chow pellets (fat: 5.6%; fiber: 4.7%; protein: 18.7%) as a less salient food reinforcer. Rats initially underwent daily 1 h training sessions with an increasing fixed-ratio (FR) schedule between days (FR1, 3, 10, 32, 100). Rats moved to a higher FR only after having reached responding criteria (criteria: FR1 > 60 pellets, FR3 > 20 pellets, FR10 > 6 pellets, FR32 > 2 pellets, FR100- no pellet requirement). All animals were trained up to FR100 prior to moving on to the thresholding task. They were then trained on a reverse thresholding procedure in which the number of lever presses required to earn a food pellet and light/tone cue decreased incrementally every 25 min (5 min access to lever-pressing followed by 20-min timeout) throughout the 105-min session (FR100, 32, 10, 3, 1). Rats were trained on the thresholding procedure for 10 days

each for palatable food, then chow, and performance on the last 5 days of training for each food reinforcer was fit to a demand curve and analyzed using the exponential demand equation described above.

## **Analysis and statistics**

Independent samples t-tests were used to determine effects of ELA on sucrose preference, M&M consumption, heroin consumption, remifentanyl low-effort dose preference, days until extinction criterion, reinstatement, and demand ( $Q_0$ ,  $\alpha$ ) for remifentanyl, and for palatable/nonpalatable foods. Extinction persistence was further analyzed for “survival” of seeking behavior (i.e., percentage of rats in each group failing to meet extinction criterion on each training day), and plots were compared using the log-rank test [22]. For analyses containing within-subjects variables (ex. saline vs. heroin primed reinstatement), mixed model ANOVAs were used, with group (ELA/CTL) as a between-subjects factor. Following significant interactions in ANOVA, Bonferroni post-hoc tests were used to characterize the nature of effects. Randomization was not used in the design of these studies, and experimenters were not blind to experimental group during testing. Compared groups did not statistically differ from one another in variance, accommodating assumptions of the parametric tests employed.

## **Results**

### **Heroin self-administration, extinction, and reinstatement**

We found strikingly augmented addiction-like behaviors for two distinct classes of opioid drugs (heroin and remifentanyl), in adult female rats raised under ELA conditions. Total heroin self-administration did not vary between control and ELA rats (Fig. 1a; CTL mean (SEM) mg/kg/rat = 13.01 (0.9687), ELA  $m = 11.37$  (0.4302);  $t_{12} = 1.550$ ;  $P = 0.1471$ ), nor did responding for remifentanyl at low effort during the demand task (mean  $\mu\text{g/kg}$  taken in first 10 min of the demand sessions: CTL = 41.79, ELA = 43.06;  $t_{29} = 0.5844$ ;  $P = 0.5634$ ; Fig. 1b). However, once heroin was withdrawn after self-administration training, the ELA group resisted extinction, a robust indicator of compulsive drug seeking [23, 24] (Fig. 1c; mean (SEM) days until criterion; CTL  $m = 5.714$  (0.4738), ELA  $m = 8.429$  (0.9724);  $t_{12} = 2.509$ ;  $P = 0.0274$ ). Although initial responding on extinction training day 1 was unaltered (no group  $\times$  15 min time bin interaction for active lever pressing:  $F(7, 84) = 1.482$ ;  $P = 0.1846$ ), the probability that ELA rats will achieve extinction criterion each day was lower than in controls (Fig. 1d; Kaplan–Meier probability of survival; CTL median survival = 6 days; ELA median survival = 8 days; Log-rank curve comparison Chi square (df) = 4.491 (1),  $P = 0.0341$ ). Moreover, post-extinction reinstatement of heroin-seeking elicited by either heroin cues or a priming dose of heroin itself was greater in ELA rats compared with CTLs; Fig. 1e, f). Notably these reinstatement measures are considered risk factors for craving and relapse to drug use in humans attempting to quit. [25, 26] Significant cue-induced and heroin-primed reinstatement was apparent in all rats (main effect of cue/no-cue:  $F(1, 12) = 89.20$ ;  $P < 0.0001$ ; main effect of heroin/saline prime:  $F(1, 12) = 27.00$ ;  $P = 0.0002$ ). However, both types of reinstatement were augmented in ELA animals (Bonferroni’s post-hocs; cue:  $t_{24} = 4.676$ ;  $P = 0.0002$ ; prime:  $t_{24} = 3.210$ ;  $P = 0.0075$ ).

## Demand for remifentanil

In humans, drug addiction is characterized by high demand for drugs that is insensitive to escalating financial, social, and health costs. This phenomenon, termed ‘demand inelasticity,’ is characteristic of economic demand for a wide range of essential commodities, and is a hallmark of compulsive drug seeking in people with substance use disorders [27, 28]. Therefore, we tested demand elasticity for an opioid drug using an established and sensitive assay of microeconomic demand [17, 18, 29]. Because this within-session protocol requires short-acting drugs which enable robust lever-pressing throughout a ~2 h session [19], we examined demand for the short-acting fentanyl analog remifentanil in control and ELA rats. This approach additionally broadened the range of drugs tested to a distinct class of abused opioids.


Remarkably, ELA-reared rats exhibited features similar to human opioid addicts [30] when given the opportunity to self-administer remifentanil. Specifically, they were willing to pay a significantly higher price to obtain the drug compared to controls—their demand became inelastic and relatively insensitive to cost (decreased  $\alpha$ ) (Fig. 2a; CTL mean (SEM) = 3.286 (0.3502), ELA mean (SEM) = 2.193 (0.2237);  $t_{28} = 2.630$ ;  $P = 0.0137$ ). The selectivity of this addictive-like behavior was striking: no effect of ELA was observed in the preferred intake of remifentanil when the drug was essentially “free”, measured as the hedonic set-point, or  $Q_0$  (Fig. 2b; CTL mean (SEM) = 15.97 (1.307), ELA mean (SEM) 17.32 (1.011);  $t_{28} = 0.8159$ ;  $P = 0.4215$ ). Accordingly, the total amount of remifentanil taken under low-effort conditions in these tests did not differ between the CTL and ELA groups (Fig. 1b). These findings align with our finding that low-effort heroin intake did not differ between groups (Fig. 1a). Average drug intake in each effort bin is shown in Fig. 2c.

## Palatable and nutritive food reward

In a typical sucrose preference assay of natural reward sensitivity, or “anhedonia” [31–33], ELA females were indistinguishable from those reared in control lab conditions, unlike prior findings in males [12]. Percent of sucrose consumption (vs. water) on the two-bottle task did not differ based on early life rearing conditions (Supplementary Fig. 1A; CTL  $m = 75.19\%$  (1.729), ELA  $m = 76.42\%$  (1.221);  $t_{22} = 0.5831$ ;  $P = 0.5657$ ). In contrast, ELA females ate more highly palatable M&M chocolates than their CTL counterparts in a separate assay of highly palatable reward intake [17] (Supplementary Fig. 1B; CTL  $m = 3.701$  g (0.2763), ELA  $m = 4.852$  g (0.2121);  $t_{14} = 3.365$ ;  $P = 0.0046$ ).


Next, we examined economic demand for highly palatable food morsels and typical nutritive chow in ELA and CTL rats. ELA rats were willing to pay a significantly higher price (in effort) for the palatable food pellets, indicating decreased demand elasticity (Fig. 2d, CTL  $\alpha m = 3.660$  (0.3865), ELA  $\alpha m = 2.503$  (0.1978);  $t_{15} = 2.341$ ,  $P = 0.0334$ ). In contrast, when the rats worked for chow pellets, no difference was seen in demand elasticity between ELA and CTL rats (Fig. 2g, CTL  $\alpha m = 3.498$  (0.2970), ELA  $m = 3.317$  (0.1909);  $t_{15} = 0.4619$ ,  $P = 0.6508$ ). Measures of baseline intake (lever presses resulting in food at low effort;  $Q_0$ ) did not differ between ELA and CTLs for either palatable food pellets or chow (Fig. 2e, h; palatable food: CTL  $m = 43.10$  (3.974), ELA  $m = 49.22$  (2.113),  $t_{15} = 1.199$ ,  $P = 0.2490$ ; chow: CTL  $m = 38.25$  (3.599), ELA  $m$

= 34.60 (1.845),  $t_{15} = 0.7922$ ,  $P = 0.4406$ ). Average food pellet consumption in each effort bin is shown in Fig. 2f, i.



**Fig. 1** Early life adversity potentiates heroin-seeking behaviors. **a** Total heroin self-administration did not differ between control and ELA rats ( $t_{12} = 1.550$ ;  $P = 0.1471$ ), nor did **(b)** remifentanyl self-administration at low effort ( $t_{29} = 0.5844$ ;  $P = 0.5634$ ). **c** Once response-contingent heroin was withdrawn, the ELA group resisted extinction more than controls ( $t_{12} = 2.509$ ;  $P = 0.0274$ ). **d** Accordingly, the probability that ELA rats achieve extinction criterion (<20 active lever presses) each day was lower than in controls (Kaplan–Meier probability of survival; Log-rank curve comparison Chi square (df) = 4.491 (1),  $P = 0.0341$ ). **e, f** ELA augmented reinstatement of heroin seeking by heroin-associated cues (main effect of cue/no cue:  $F(1, 12) = 89.20$ ;  $P < 0.0001$ ; main effect of rearing condition:  $F(1, 12) = 9.982$ ;  $P = 0.0082$ ; cue x ELA interaction:  $F(1, 12) = 12.49$ ;  $P = 0.0041$ . Bonferroni’s post-hoc tests CTL vs ELA: no cue:  $t_{24} = 0.2543$ ;  $P > 0.9999$ ; cue:  $t_{24} = 4.676$ ;  $P = 0.0002$ ), and by a heroin priming injection (main effect of heroin/saline prime:  $F(1, 12) = 27.00$ ;  $P = 0.0002$ ; main effect of rearing condition:  $F(1, 12) = 4.891$ ;  $P = 0.0471$ ; prime x ELA interaction:  $F(1, 12) = 5.447$ ;  $P = 0.0378$ . Bonferroni’s post-hoc tests CTL vs ELA: saline prime:  $t_{24} = 0.01554$ ;  $P > 0.9999$ ; heroin prime:  $t_{24} = 3.210$ ;  $P = 0.0075$ ). Circles within each bar represent individual animals in CTL (green) and ELA (orange) groups. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$





**Fig. 2** Early life adversity increases demand for opioids and highly palatable food. **a** ELA-reared rats had a decreased sensitivity to cost, or an ‘inelastic’ demand, for remifentanil compared with controls ( $t_{28} = 2.630$ ;  $P = 0.0137$ ). **b** However, no changes were observed in the intake of remifentanil by the ELA group when the drug was essentially “free”, measured as the hedonic set-point, or  $Q_0$  ( $t_{28} = 0.8159$ ;  $P = 0.4215$ ). **c** Average ( $\pm$  SEM) drug intake at each effort step is depicted. **d** ELA rats were willing to pay a significantly higher price (effort) for a highly palatable food, indicating decreased demand elasticity, or  $\alpha$  ( $t_{15} = 2.341$ ,  $P = 0.0334$ ), whereas **(e)** consumption at low effort ( $Q_0$ ) did not differ between ELA and CTL rats ( $t_{15} = 1.199$ ,  $P = 0.2490$ ). **f** Average palatable food intake at each effort step is depicted. **g** In contrast to palatable food, no difference was seen in demand elasticity ( $\alpha$ ) between ELA and CTL rats for chow pellets ( $t_{15} = 0.4619$ ,  $P = 0.6508$ ), and **(h)** Chow consumption at low effort ( $Q_0$ ) also did not differ between ELA and CTLs ( $t_{15} = 0.7922$ ,  $P = 0.4406$ ). **i** Average chow pellet intake at each effort step is depicted. Circles within each bar represent individual animals in CTL (green) and ELA (orange) groups. \* $p < 0.05$

## Discussion

Together, our findings indicate that in a preclinical experimental system where genetics and prior existing conditions can be controlled, poverty-like rearing during sensitive developmental periods [34, 35] can lead to vulnerability to the addictive effects of opioid drugs. Indeed, the findings suggest that critical developmental periods—such as those which are well-defined for sensory circuits [34, 35] apply also to developing reward circuitries, and potentially to other cognitive and emotional brain systems as well [11, 12, 14, 36].

The present results reveal that the consequences of aberrant reward circuit development caused by ELA may differ between males and females. For example, ELA in females here led to exaggerated pursuit of heroin and remifentanyl, coupled with increased motivation for highly palatable food (sweet banana pellets or chocolate), without impacting intake of less salient food rewards (chow pellets or a dilute sucrose solution). In contrast, we previously showed in males that ELA induces persistent anhedonia for food (sucrose preference; M&M intake) and social play [12]. Males also exhibited a lower hedonic set-point to an addictive drug in the demand elasticity test, though the drug was cocaine rather than an opioid [17]. We note that the remarkable ability of ELA to increase motivation and demand for certain highly hedonic rewards specifically in females may help explain the prevalence of ELA in heroin-addicted women [6].

Notably, our findings suggest that the influence of ELA on the normal maturation of reward circuits may differ in males and females, potentially affecting distinct circuit nodes or molecularly defined pathways [37]. Our findings highlight the importance of attention to sex differences in future mechanistic studies of ELA-related opioid addiction, and in tests of prevention or intervention strategies for this problem.

The specific aspects of early life adversity that cause these effects, and the mechanisms by which ELA generates addiction-like behavior, remain to be explored. Our prior work demonstrated that ELA (using our naturalistic LBN model) is characterized by chaotic, unpredictable maternal signals to the developing pups [31], and converging evidence from both humans and rodents shows that such unpredictable, fragmented early life environments profoundly impact brain function later in life [32] i.e., into adolescence [14, 38, 39] and persisting into adulthood [12, 17, 40]. A potential mechanism for these long-term negative outcomes, including opioid addiction risk, is aberrant maturation of specific reward- and stress-related brain circuits, a finding that also emerges in studies using translatable methods such as structural magnetic resonance imaging [11].

Whereas numerous aspects of addiction vulnerability we have discovered here require further investigation (including sensitivity to opiate drug dosages [41, 42]), the present results set the groundwork for mechanistic studies of the underlying alterations in reward circuit functions. Importantly, it creates for the first time a direct causal link between ELA and opioid addiction vulnerability, and establishes a new framework for testing mechanisms across species, ultimately enabling the development of predictive biomarkers for, and prevention of opioid addiction.

## Data availability

The data forming the basis of these studies do not include genomic or imaging data sets storable in public repositories. Data will be readily made available when requested from the authors.

**Acknowledgements** We thank the National Institute on Drug Abuse (NIDA) Drug Supply Program (Research Triangle Park, NC, USA), for providing heroin and remifentanyl.

**Funding** The research was supported in part by NIH grants MH096889; NS28912; DA035251; DA044118; GM008620; MH119049 and the Hewitt Foundation for Biomedical Research

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

1. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. <https://doi.org/10.1056/NEJMsr1706626>. 2017.
2. Morrow JD, Fligel SB. Neuroscience of resilience and vulnerability for addiction medicine: From genes to behavior. *Prog Brain Res*. 2016;223:3–18.
3. Cates HM, Benca-Bachman CE, de Guglielmo G, Schoenrock SA, Shu C, Kallupi M. National Institute on Drug Abuse genomics consortium white paper: Coordinating efforts between human and animal addiction studies. *Genes Brain Behav*. 2019; 18:e12577.
4. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. *Am J Public Health*. 2009; 99:221–7.
5. Gershon A, Minor K, Hayward C. Gender, victimization, and psychiatric outcomes. *Psychol Med*. 2008;38:1377–91.
6. Shand FL, Degenhardt L, Slade T, Nelson EC. Sex differences amongst dependent heroin users: Histories, clinical characteristics and predictors of other substance dependence. *Addict Behav*. 2011;36:27–36.
7. Widom CS, Marmorstein NR, White HR. Childhood victimization and illicit drug use in middle adulthood. *Psychol Addict Behav*. 2006;20:394–403.
8. Marsh JC, Park K, Lin YA, Bersamira C. Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007–2014. *J Subst Abus Treat*. 2018;87:79–85.
9. Enoch M-A. The role of early life stress as a predictor for alcohol and drug dependence. *Psychopharmacology*. 2011;214:17–31.

10. Danese A, Moffitt TE, Arseneault L, Bleiberg BA, Dinardo PB, Gandelman SB, et al. The origins of cognitive deficits in victimized children: implications for neuroscientists and clinicians. *Am J Psychiatry*. 2017;174:349–61.
11. Chen Y, Baram TZ. Toward understanding how early-life stress reprograms cognitive and emotional brain networks. *Neuropsychopharmacology*. 2016;41:197.
12. Bolton JL, Molet J, Regev L, Chen Y, Rismanchi N, Haddad E, et al. Anhedonia following early-life adversity involves aberrant interaction of reward and anxiety circuits and is reversed by partial silencing of amygdala corticotropin-releasing hormone gene. *Biol Psychiatry*. 2018;83:137–47.
13. Ivy AS, Brunson KL, Sandman C, Baram TZ. Dysfunctional nurturing behavior in rat dams with limited access to nesting material: a clinically relevant model for early-life stress. *Neuroscience*. 2008;154:1132–42.
14. Molet J, Heins K, Zhuo X, Mei YT, Regev L, Baram TZ et al. Fragmentation and high entropy of neonatal experience predict adolescent emotional outcome. *Transl Psychiatry*. 2016;6:e702.
15. Molet J, Maras PM, Avishai-Eliner S, Baram TZ. Naturalistic rodent models of chronic early-life stress. *Dev Psychobiol*. 2014; 56:1675–88.
16. Smith RJ, Aston-Jones G. Orexin / hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. *Eur J Neurosci*. 2012;35:798–804.
17. Bolton JL, Ruiz CM, Rismanchi N, Sanchez GA, Castillo E, Huang J, et al. Early-life adversity facilitates acquisition of cocaine self-administration and induces persistent anhedonia. *Neurobiol Stress*. 2018;8:57–67.
18. Porter-Stransky KA, Bentzley BS, Aston-Jones G. Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanyl. *Addict Biol*. 2017;22:303–17.
19. Bentzley BS, Fender KM, Aston-Jones G. The behavioral economics of drug self-administration: a review and new analytical approach for within-session procedures. *Psychopharmacology*. 2013;226:113–25.
20. Oleson EB, Roberts D. Parsing the addiction phenomenon: Self-administration procedures modeling enhanced motivation for drug and escalation of drug intake. *Drug Discov Today*. 2009;5:217–26.
21. Cox BM, Bentzley BS, Regen-Tuero H, See RE, Reichel CM, Aston-Jones G. Oxytocin acts in nucleus accumbens to attenuate methamphetamine seeking and demand. *Biol Psychiatry*. 2017; 81:949–58.
22. Bland JM, Altman DG. The logrank test. *BMJ* 2004;328:1073.
23. Milton AL, Everitt BJ. The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments. *Neurosci Biobehav Rev*. 2012;36:1119–39.

24. Vanderschuren LJ, Ahmed SH. Animal studies of addictive behavior. *Cold Spring Harb Perspect Med.* 2013;3:a011932.
25. Weiss F. Neurobiology of craving, conditioned reward and relapse. *Curr Opin Pharm.* 2005;5:9–19.
26. Brandon TH, Vidrine JI, Litvin EB. Relapse and relapse prevention. *Annu Rev Clin Psychol.* 2007;3:257–84.
27. Bickel WK, Johnson MW, Koffarnus MN, MacKillop J, Murphy JG. The behavioral economics of substance use disorders: reinforcement pathologies and their repair. *Annu Rev Clin Psychol.* 2014;10:641–77.
28. Hursh SR. Economic concepts for the analysis of behavior. *J Exp Anal Behav.* 1980;34:219–38.
29. Bentzley BS, Zhou TC, Aston-Jones G. Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat. *Proc Natl Acad Sci.* 2014;111:11822–7.
30. Strickland JC, Lile JA, Stoops WW. Evaluating non-medical prescription opioid demand using commodity purchase tasks: test-retest reliability and incremental validity. *Psychopharmacology.* 2019;236:2641–52.
31. Slattery DA, Cryan JF. Modelling depression in animals: at the interface of reward and stress pathways. *Psychopharmacology.* 2017;234:1451–65.
32. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. *Trends Neurosci.* 2012;35:68–77.
33. Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. *Nat Rev Neurosci.* 2013;14:609–25.
34. Espinosa JS, Stryker MP. Development and plasticity of the primary visual cortex. *Neuron.* 2012;75:230–49.
35. Barkat TR, Polley DB, Hensch TK. A critical period for auditory thalamocortical connectivity. *Nat Neurosci.* 2011;14: 1189–94.
36. Davis EP, Stout SA, Molet J, Vegetabile B, Glynn LM, Sandman CA, et al. Exposure to unpredictable maternal sensory signals influences cognitive development across species. *Proc Natl Acad Sci USA.* 2017;114:10390–5.
37. Rincón-Cortés M, Herman JP, Lupien S, Maguire J, Shansky RM. Stress: Influence of sex, reproductive status and gender. *Neurobiol Stress.* 2019;10:100155.
38. Luby JL, Barch D, Whalen D, Tillman R, Belden A. Association between early life adversity and risk for poor emotional and physical health in adolescence: a putative mechanistic neurodevelopmental pathway. *JAMA Pediatr.* 2017; 171:1168–75.

39. Doherty TS, Blaze J, Keller SM, Roth TL. Phenotypic outcomes in adolescence and adulthood in the scarcity-adversity model of low nesting resources outside the home cage. *Dev Psychobiol.* 2017;59:703–14.
40. Goodwill HL, Manzano-Nieves G, Gallo M, Lee H-I, Oyerinde E, Serre T et al. Early life stress leads to sex differences in development of depressive-like outcomes in a mouse model. *Neuropsychopharmacology.* 2019;44:711–720.
41. Mavrikaki M, Pravetoni M, Page S, Potter D, Chartoff E. Oxycodone self-administration in male and female rats. *Psycho-pharmacology.* 2017;234:977–87.
42. Cicero TJ, Aylward SC, Meyer ER. Gender differences in the intravenous self-administration of mu opiate agonists. *Pharm Biochem Behav.* 2003;74:541–9.

Supplementary information The online version of this article (<https://doi.org/10.1038/s41380-019-0628-5>) contains supplementary material, which is available to authorized users.

Tallie Z. Baram                      [tallie@uci.edu](mailto:tallie@uci.edu)  
Stephen V. Mahler                [mahlers@uci.edu](mailto:mahlers@uci.edu)

- <sup>1</sup>Department of Neurobiology & Behavior, University of California—Irvine, Irvine, CA, USA
- <sup>2</sup>Department of Anatomy & Neurobiology, University of California—Irvine, Irvine, CA, USA
- <sup>3</sup>Department of Psychiatry, Stanford University, Stanford, CA, USA
- <sup>4</sup>Department of Pediatrics, University of California—Irvine, Irvine, CA, USA